All seven SMARCA4/KRAS co-mutation NSCLC publications in this review showed either a significantly worse PFS or OS as compared to SMARCA4 WT/KRAS mutation analyses across standard-of-care cancer treatments or within a specific treatment analysis (i.e., KRAS G12C inhibitor, ICIs, or non-ICIs) [8,21,22,34,35,36,37]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.